openPR Logo
Press release

Acute Myeloid Leukemia Market Insights, Epidemiology and Market Forecast – 2027

08-24-2018 01:44 PM CET | Health & Medicine

Press release from: ReportsnReports

Acute Myeloid Leukemia Market

Acute Myeloid Leukemia Market

Acute Myeloid Leukemia - Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Acute Myeloid Leukemia in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Acute Myeloid Leukemia from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Sample Research Report at https://www.reportsnreports.com/contacts/requestsample.aspx?name=1329403

Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain and the United Kingdom)
- Japan

Study Period: 2016-2027
Acute Myeloid Leukemia - Disease Understanding and Treatment Algorithm
Acute Myeloid Leukemia (AML) is the fastest growing cancer that occurs when the bone marrow begins to make cells that have not yet completely matured also known as blasts. These blasts usually develops in the white blood cells. In AML, these cells do not develop and are unable to ward off infections. In Acute Myeloid Leukemia, bone marrow may also make abnormal red cells and platelets which increases rapidly, and the abnormal (leukemia) cells begin to crowd out the normal white blood cells, red blood cells and platelets that the body needs.

The DelveInsight Acute Myeloid Leukemia market report gives the thorough understanding of the Acute Myeloid Leukemia by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Acute Myeloid Leukemia in the US, Europe, and Japan.

Get Discount on this Research Report at https://www.reportsnreports.com/contacts/discount.aspx?name=1329403

Acute Myeloid Leukemia Epidemiology
The Acute Myeloid Leukemia epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented as Incident Cases, Age Specific Prevalence, Incidence of Relapsed/Refractory cases and Diagnosed population] scenario of Acute Myeloid Leukemia in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.

As per American Cancer Society, approximately 19,520 new cases of Acute Myeloid Leukemia are estimated in 2018. Around 10,670 number of patients are expected to die due to Acute Myeloid Leukemia.

Acute Myeloid Leukemia Drug Chapters
This segment of the Acute Myeloid Leukemia report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

The typical treatments of AML involve chemotherapies which is divided into two phases i.e. induction and consolidation phase. Chemotherapy such as Cladribine, Topotecan, Etoposide, Methotrexate and Azacitidine are recommended for killing the cancer cells. The targeted therapies are used in case when chemo no longer responds. Targeted therapy such as Enasidenib, Gemtuzumab and Midostaurin are recommended for treating Acute Myeloid Leukemia. Two promising therapies has recently entered the AML market; enasidenib (Idhifa) and liposomal cytarabine-daunorubicin CPX-351 (Vyxeos). Idhifa (enasidenib) is approved for the treatment of relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation by U.S. Food and Drug Administration (FDA).

Direct Purchase of this Research Report at https://www.reportsnreports.com/purchase.aspx?name=1329403

Acute Myeloid Leukemia Market Outlook
The Acute Myeloid Leukemia market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
There are many potential candidates in the development phase for the treatment of Acute Myeloid Leukemia such as Gilteritinib by Astellas Pharma Inc., Pracinostat by Helsinn Healthcare S.A., OCV-501 and Guadecitabine (SGI-110) by Otsuka Pharmaceutical Co., Ltd., Iomab-B CD45 and Actimab-A (f.d.) CD33 by Actinium Pharmaceuticals, Inc., BST-236 by BioSight Ltd., etc. These drugs are expected to get launched in the study period from 2016-2027 and are going to create remarkable impact on Acute Myeloid Leukemia market.

Acute Myeloid Leukemia Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

Browse Complete Report at https://www.reportsnreports.com/reports/1329403-acute-myeloid-leukemia-aml-market-insight-epidemiology-and-market-forecast-2027.html

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Acute Myeloid Leukemia Report Insights
- Patient Population
- Therapeutic Approaches
- Pipeline Analysis
- Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies

Acute Myeloid Leukemia Report Key Strengths
- 10 Years Forecast
- 7MM Coverage
- Epidemiology Segmentation
- Sub-type Segmentation
- Key Cross Competition
- Highly Analyzed Market
- Drugs Uptake

Acute Myeloid Leukemia Report Assessment
- Current Treatment Practices
- Unmet Needs
- Pipeline Product Profiles
- Market Attractiveness
- Market Drivers and Barriers

Key Benefits
- This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Acute Myeloid Leukemia market
- Organize sales and marketing efforts by identifying the best opportunities for Acute Myeloid Leukemia market
- To understand the future market competition in the Acute Myeloid Leukemia market.

ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

+ 1 888 391 5441
sales@reportsandreports.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Acute Myeloid Leukemia Market Insights, Epidemiology and Market Forecast – 2027 here

News-ID: 1200199 • Views:

More Releases from ReportsnReports

DeviceCon Series 2024 - UK Edition | MarketsandMarkets
DeviceCon Series 2024 - UK Edition | MarketsandMarkets
Future Forward: Redefining Healthcare with Cutting-Edge Devices Welcome to DeviceCon Series 2024 - Where Innovation Meets Impact! Join us on March 21-22 at Millennium Gloucester Hotel, 4-18 Harrington Gardens, London SW7 4LH for a groundbreaking convergence of knowledge, ideas, and technology. MarketsandMarkets proudly presents the DeviceCon Series, an extraordinary blend of four conferences that promise to redefine the landscape of innovation in medical and diagnostic devices. Register Now @ https://events.marketsandmarkets.com/devicecon-series-uk-edition-2024/register MarketsandMarkets presents
5th Annual MarketsandMarkets Infectious Disease and Molecular Diagnostics Conference Promises New Trends and Insights in Diagnosis
5th Annual MarketsandMarkets Infectious Disease and Molecular Diagnostics Confer …
London, March 7, 2024 - MarketsandMarkets is thrilled to announce the eagerly awaited 5th Annual Infectious Disease and Molecular Diagnostics Conference, scheduled to take place on March 21st - 22nd, 2024, at the prestigious Millennium Gloucester Hotel, located at 4-18 Harrington Gardens, London SW7 4LH. This conference promises to be a groundbreaking event, showcasing the latest trends and insights in diagnosis, as well as unveiling cutting-edge technologies that are revolutionizing the
Infection Control, Sterilization & Decontamination Conference |21st - 22nd March 2024| Challenges and Factors affecting in Sterilization of medical devices and more
Infection Control, Sterilization & Decontamination Conference |21st - 22nd March …
MarketsandMarkets is pleased to announce its 8th Annual Infection Control, Sterilisation, and Decontamination in Healthcare Conference, which will take place March 21-22, 2024, in London, UK. With the increased risk of infection due to improper sterilisation and decontamination practices, the safety of patients and healthcare workers is of paramount importance nowadays. Enquire Now @ https://events.marketsandmarkets.com/infection-control-sterilization-and-decontamination-conference/ This conference aims to bring together all the stakeholders to discuss the obstacles in achieving
Breast Augmentation Market Key Players, Demands, Cost, Size, Procedure, Shape, Surface and Forecast to 2025
Breast Augmentation Market Key Players, Demands, Cost, Size, Procedure, Shape, S …
The global Breast Augmentation Market in terms of revenue was estimated to be worth $900 million in 2020 and is poised to reach $1,692 million by 2025, growing at a CAGR of 13.4% from 2020 to 2025. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying

All 5 Releases


More Releases for Acute

Acute Conjunctivitis Treatment Market: The Future Insights Of Global Acute Conju …
Acute Conjunctivitis Treatment Market Acute Conjunctivitis Treatment Market, or pink eye, is an irritation or inflammation of the conjunctiva that covers the white part of the eyeball. It can be caused by allergies or a bacterial or viral infection. Acute Conjunctivitis Treatment Market can be highly communicable and can be spread easily by the contact with secretions of eye from the infected person. Conjunctivitis often resolves on its own, but
Pipeline Review, H2 2017 of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic …
"Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2017" The Report covers current Industries Trends, Worldwide Analysis, Global Forecast, Review, Share, Size, Growth, Effect. . . Description- '
Acute Renal Failure (ARF) (Acute Kidney Injury) Market: Industry Size, Share, Gr …
Latest industry research report on: Acute Renal Failure (ARF) (Acute Kidney Injury) Market : Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2017, provides an overview of the Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline landscape. Request For Sample Report
Acute Renal Failure (ARF) (Acute Kidney Injury) Pipeline Review, H2
Market Research Hub (MRH) has recently announced the addition of a fresh report, titled “Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2017” to its report offerings. The report covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1230595 Acute kidney failure occurs when kidneys suddenly become unable to filter waste products from blood.
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical T …
ReportsWorldwide has announced the addition of a new report title Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical Trials Review, H1, 2017 to its growing collection of premium market research reports. GlobalData's clinical trial report, “Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical Trials Review, H1, 2017" provides an overview of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) clinical trials scenario. This report provides top line data relating to
H2 2016 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeut …
Albany, New York, January 03, 2017: A recent forecast report focusing on the Acute Myelocytic Leukemia Market has been added to the wide portfolio of Market Research Hub (MRH). It is entitled as, “Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2016” which has been equipped by in-depth market examination with inputs from the industry experts. It covers the current market scenario and also its future growth